Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
1(5%)
Results Posted
69%(11 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
8
42%
Ph phase_3
3
16%
Ph early_phase_1
1
5%
Ph phase_1
2
11%
Ph phase_4
4
21%

Phase Distribution

3

Early Stage

8

Mid Stage

7

Late Stage

Phase Distribution18 total trials
Early Phase 1First-in-human
1(5.6%)
Phase 1Safety & dosage
2(11.1%)
Phase 2Efficacy & side effects
8(44.4%)
Phase 3Large-scale testing
3(16.7%)
Phase 4Post-market surveillance
4(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

1

trials recruiting

Total Trials

19

all time

Status Distribution
Active(1)
Completed(16)
Terminated(2)

Detailed Status

Completed16
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.6%)
Phase 12 (11.1%)
Phase 28 (44.4%)
Phase 33 (16.7%)
Phase 44 (22.2%)

Trials by Status

completed1684%
recruiting15%
terminated211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT06122090Phase 2

Treatment of Hypopigmented Scars With Bimatoprost

Recruiting
NCT03825380Phase 3

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Completed
NCT04738149Early Phase 1

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

Completed
NCT02358369Phase 2

Dose-Ranging Study of the Bimatoprost Ocular Insert

Completed
NCT02537015Phase 2

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Completed
NCT02143843Phase 2

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Completed
NCT02742649Phase 1

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed
NCT01915940Phase 2

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Completed
NCT02676310Phase 1

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Terminated
NCT02059655Phase 4

Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)

Completed
NCT00705757Phase 4

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed
NCT02170662Phase 2

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Completed
NCT01646151

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed
NCT02154217Phase 3

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Completed
NCT01291108Phase 2

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT01655758Phase 4

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Completed
NCT00300443Phase 2

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Completed
NCT00348062Phase 4

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19